Zai Lab Revenue Triples, as It Struggles to Break Cycle of Mounting Losses
The biotech company is bringing in bigger sums from its growing stable of drugs approved for sale in China, but is also accelerating its R&D spending Key takeaways: Zai Lab…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
